Radioactive waste advisers training course

Course dates

Monday 5 - Wednesday 7 October 2026. 

Venue

The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK.

Waste adviser wearing protective uniform surveying barrels of radioactive waste

Credit: AP Photo/Lee Jin-man

This course is organised by the Joint Department of Physics of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London.

Course outline

This course provides the theoretical background and training necessary for the management of unsealed and sealed radioactive substances in hospitals.

The first day covers the following subject areas: interaction and units, instrumentation, radiation effects and risks and the regulatory framework. The following two days cover the legislation, applying for a Permit and compliance with the Permit conditions, the transport regulations and practical management of radioactive substances in hospitals. As well as lectures, there will be workshop sessions covering some practical issues. This course focusses on the Environmental Permitting (England and Wales) Regulations 2016.

The course is at a level suitable for hospital physicists working in the field of radiation protection or those who want to expand their knowledge in this field. It is particularly suitable for those wishing to become Radioactive Waste Advisers (RWA), and covers the Basic Underpinning Knowledge (Basic Syllabus) as set out in the RPA2000 Guidance.

This is a CPD course approved by IPEM.  

Those wishing to use the course towards RWA certification can sit an optional marked short exam.

Provisional Lecture List

Day 1: Review and effects of radiation

  • Interactions and units
  • Instrumentation
  • Sources of exposures
  • Risks and effects
  • Radiation protection framework
  • Other legislation

Day 2: Statutory requirements

  • EPR2016
  • Cradle to grave: records management
  • Transport Regulations
  • Applying for an environmental permit
  • IRAT2
  • Permit compliance / BAT

Day 3: Radioactive source management in hospitals

  • HASS and other sealed sources
  • Security
  • RWA certification
  • RWA Portfolio Assessment
  • Optional assessment

Workshops

  • EPR audits
  • Incidents

The organisers may need to alter the final programme to fulfil practical commitments.

Course fees

 Full three days including first day review: Two-day module excluding 1st day review (for those who have already attended RPTC in past 5 years) 
Payments received on or before 7 August 2026

 £460

£320

Payments received after 7 August 2026

 £525

£380

The cost includes lunches and light refreshments. Lecture notes and a certificate of attendance are provided.

Registration

Online Registration Form

Downloadable Registration Form

You will be allocated a place on receipt of a completed registration form and purchase order or completed online payment. We are unable to accept provisional bookings.

The number of participants is limited, so early booking is advised.  Applications from outside the UK are welcome.

Closing date for registrations: Friday 11 September 2026

Related documents

2 Day Course - Provisional Timetable 2026

3 Day Course - Provisional Timetable 2026

Sutton Site Map

Contacts

Course organiser: Dr Allison Craig 

For registration details and any other queries contact:

Course administrator: Mrs Jessica Keegan.

 

Latest ICR News

Image of immunofluorescence staining of bladder tumour tissue. Some areas appear lighter green, some dark blue, and others black.
Immunotherapy boost can spare more bladder cancer patients major surgery

02/06/26

An immunotherapy helps bladder cancer patients remain cancer free and enables them to avoid surgery, a phase II trial has found.
See full story
Histopathologic image illustrating squamous cell carcinoma.
Immunotherapy injection shrinks tumours in patients with recurrent and/or metastatic head and neck cancer

31/05/26

A targeted cancer treatment given via a simple injection under the skin shrank tumours in more than one third of patients with recurrent and/or metastatic head and neck cancer whose disease has stopped responding to standard treatments, according to research led by scientists at The Institute of Cancer Research, London
See full story
Image of pill bottle with pills spilling out
New targeted therapy shrinks advanced gastrointestinal tumours for 61 per cent of patients in an early study

30/05/26

A new, targeted cancer therapy for advanced gastrointestinal stromal tumours (GIST) has shown promising early results, with 61 per cent of patients who received velzatinib as first-line treatment experiencing tumour shrinkage of 30 per cent or over. The results could pave the way for a larger trial to evaluate this therapy as a first-line alternative to imatinib, which has been the standard treatment for more than two decades.
See full story
Big Bang moment in bowel cancer research
Targeted therapy shows promise for patients with advanced colorectal cancer in a first-in-human study

30/05/26

A targeted antibody therapy combined with standard chemotherapy has shown early signs of tumour shrinkage and disease control in patients with advanced bowel cancer, according to new Phase I clinical trial results from The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust.
See full story